Antileprosy drugs.
D000743:Anemia, Hemolytic / Q000139:chemically induced; D000814:Aniline Compounds / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003622:Dapsone / Q000008:administration & dosage / Q000009:adverse effects; D004352:Drug Resistance, Microbial; D006801:Humans; D007273:Injections, Intramuscular; D007918:Leprosy / Q000188:drug therapy*; D009166:Mycobacterium leprae / Q000187:drug effects; D010619:Phenazines / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013450:Sulfones / Q000627:therapeutic use; D013828:Thioacetazone / Q000627:therapeutic use; D013890:Thiourea / Q000627:therapeutic use
D000814:Aniline Compounds; D000900:Anti-Bacterial Agents; D010619:Phenazines; D013449:Sulfonamides; D013450:Sulfones; D003622:Dapsone; D013890:Thiourea; D013828:Thioacetazone; D012293:Rifampin